Diabetes Treatment Options: Expert Guide to Metformin, Ozempic, Mounjaro

With World Diabetes Day on November 14 drawing focus to the chronic condition affecting millions across South Asia, medical experts are clarifying the roles of three widely-used medications in diabetes management. Metformin, Ozempic, and Mounjaro represent different treatment approaches, each suited to particular patient profiles and disease stages.

Metformin remains the first-line treatment for type 2 diabetes, particularly in early-stage disease management. The medication works by reducing glucose production in the liver and improving insulin sensitivity. Its long safety record, affordability, and proven efficacy over decades have made it the standard initial prescription across India and the region.

Ozempic and Mounjaro represent newer pharmacological classes targeting different metabolic pathways. These glucagon-like peptide-1 (GLP-1) receptor agonists and tirzepatide-based drugs work by enhancing insulin secretion, slowing gastric emptying, and promoting weight loss. Such medications are typically considered when metformin alone proves insufficient or in patients requiring additional cardiovascular and renal protection.

Selection between these treatments depends on individual patient factors including disease duration, comorbidities, kidney function, and treatment goals. Endocrinologists emphasize that medication choice should be personalized, considering both efficacy and accessibility. For many patients in India, metformin remains the cornerstone therapy, while newer agents serve specific clinical scenarios requiring intensified glucose control or additional metabolic benefits.

Healthcare providers stress that medication forms only one component of diabetes management. Lifestyle modifications including dietary changes, regular physical activity, and weight management remain fundamental to effective disease control alongside pharmacological intervention.